Valeant Pharmaceuticals Intl (NYSE:VRX) reported earnings this Morning, coming in at $0.98 per share, beating Wall Street’s estimates of $0.96 per Share. Revenue for the quarter came in at $2.16 billion missing the streets estimates of $2.18 billion Recent Insider Trading for Valeant Pharmaceuticals Intl (NYSE:VRX)
- On 11/16/2017 John Paulson, Director, bought 344,216 with an average share price of $14.40 per share and the total transaction amounting to $4,956,710.40.
- On 8/21/2017 Schutter Richard U De, Director, bought 10,000 with an average share price of $14.33 per share and the total transaction amounting to $143,300.00.
- On 5/11/2017 Schutter Richard U De, Director, bought 20,000 with an average share price of $13.90 per share and the total transaction amounting to $278,000.00.
- On 3/15/2017 Schutter Richard U De, Director, bought 10,000 with an average share price of $10.80 per share and the total transaction amounting to $108,000.00.
- On 3/14/2017 Paul Herendeen, CFO, bought 24,000 with an average share price of $10.72 per share and the total transaction amounting to $257,280.00.
- On 3/14/2017 Valueact Capital Master Fund,, Insider, bought 3,000,000 with an average share price of $10.82 per share and the total transaction amounting to $32,460,000.00.
Recent Trading for Valeant Pharmaceuticals Intl (NYSE:VRX) Shares of Valeant Pharmaceuticals Intl closed the previous trading session at 17.37 down -1.15 6.21% with 17.540000915527344 shares trading hands.